Medtronic plc (MDTC34) - Net Assets
Based on the latest financial reports, Medtronic plc (MDTC34) has net assets worth R$48.65 Billion BRL (≈ $9.55 Billion USD) as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$91.35 Billion ≈ $17.92 Billion USD) and total liabilities (R$42.69 Billion ≈ $8.38 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Medtronic plc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$48.65 Billion |
| % of Total Assets | 53.26% |
| Annual Growth Rate | -0.66% |
| 5-Year Change | -6.48% |
| 10-Year Change | N/A |
| Growth Volatility | 2.34 |
Medtronic plc - Net Assets Trend (2019–2025)
This chart illustrates how Medtronic plc's net assets have evolved over time, based on quarterly financial data. Also explore MDTC34 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Medtronic plc (2019–2025)
The table below shows the annual net assets of Medtronic plc from 2019 to 2025. For live valuation and market cap data, see Medtronic plc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | R$48.26 Billion ≈ $9.47 Billion |
-3.90% |
| 2024-04-30 | R$50.21 Billion ≈ $9.85 Billion |
-2.46% |
| 2023-04-30 | R$51.48 Billion ≈ $10.10 Billion |
-2.35% |
| 2022-04-30 | R$52.72 Billion ≈ $10.35 Billion |
+2.17% |
| 2021-04-30 | R$51.60 Billion ≈ $10.13 Billion |
+1.43% |
| 2020-04-30 | R$50.87 Billion ≈ $9.98 Billion |
+1.31% |
| 2019-04-30 | R$50.21 Billion ≈ $9.85 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medtronic plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 95.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | R$31.48 Billion | 65.54% |
| Common Stock | R$128.19K | 0.00% |
| Other Components | R$16.55 Billion | 34.46% |
| Total Equity | R$48.02 Billion | 100.00% |
Medtronic plc Competitors by Market Cap
The table below lists competitors of Medtronic plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cambricon Technologies Corp Ltd
SHG:688256
|
$104.90 Billion |
|
CME Group Inc
NASDAQ:CME
|
$105.05 Billion |
|
Sanofi
F:SNW2
|
$105.72 Billion |
|
Bank of Montreal
TO:BMO
|
$105.76 Billion |
|
Mizuho Financial Group Inc.
NYSE:MFG
|
$104.09 Billion |
|
AIR LIQUIDE ADR 1/5/EO 11
F:AILA
|
$103.86 Billion |
|
INTESA SANPAOLO ADR/6
F:IESJ
|
$103.85 Billion |
|
Trane Technologies plc
NYSE:TT
|
$103.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medtronic plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 50,214,000,000 to 48,024,000,000, a change of -2,190,000,000 (-4.4%).
- Net income of 4,663,000,000 contributed positively to equity growth.
- Dividend payments of 3,589,000,000 reduced retained earnings.
- Share repurchases of 2,727,000,000 reduced equity.
- New share issuances of 508,000,000 increased equity.
- Other factors decreased equity by 1,045,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$4.66 Billion | +9.71% |
| Dividends Paid | R$3.59 Billion | -7.47% |
| Share Repurchases | R$2.73 Billion | -5.68% |
| Share Issuances | R$508.00 Million | +1.06% |
| Other Changes | R$-1.04 Billion | -2.18% |
| Total Change | R$- | -4.36% |
Book Value vs Market Value Analysis
This analysis compares Medtronic plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-04-30 | R$37.36 | R$208.39 | x |
| 2020-04-30 | R$37.83 | R$208.39 | x |
| 2021-04-30 | R$38.23 | R$208.39 | x |
| 2022-04-30 | R$39.49 | R$208.39 | x |
| 2023-04-30 | R$38.69 | R$208.39 | x |
| 2024-04-30 | R$38.29 | R$208.39 | x |
| 2025-04-30 | R$37.46 | R$208.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medtronic plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.71%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.90%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.91x
- Recent ROE (9.71%) is above the historical average (8.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 9.25% | 15.16% | 0.34x | 1.79x | R$-378.10 Million |
| 2020 | 9.44% | 16.56% | 0.32x | 1.79x | R$-284.70 Million |
| 2021 | 7.01% | 11.97% | 0.32x | 1.81x | R$-1.54 Billion |
| 2022 | 9.59% | 15.90% | 0.35x | 1.73x | R$-216.10 Million |
| 2023 | 7.30% | 12.03% | 0.34x | 1.77x | R$-1.39 Billion |
| 2024 | 7.32% | 11.36% | 0.36x | 1.79x | R$-1.35 Billion |
| 2025 | 9.71% | 13.90% | 0.37x | 1.91x | R$-139.40 Million |
Industry Comparison
This section compares Medtronic plc's net assets metrics with peer companies in the Medical Devices industry.
No peer company data available for comparison.
About Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor sy… Read more